Literature DB >> 16785334

Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States.

Randall S Stafford1, Veronica Monti, Curt D Furberg, Jun Ma.   

Abstract

Medication choices for the treatment of elevated blood pressure have a large potential impact on both patient outcomes and health care costs. Historic trends of prescribing for hypertension will advance the understanding of physician practice of evidence-based medicine. This study describes both long- and short-term trends in US antihypertensive prescribing from 1990 through 2004. Data were extracted from the National Disease and Therapeutic Index, a continuing survey of a national sample of US office-based physicians. Cox and Stuart and z tests were performed. Diuretics ranked among the top 3 antihypertensive drug classes throughout the entire study time span. Angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs) were preferred over diuretics beginning in 1993, with diuretics surpassing CCBs in 2000. Beta-blockers were consistently the fourth most common class until 2002, when exceeded by angiotensin II receptor antagonists (ARBs). Most recent trends indicated an immediate but short-lived increase in the prescription of thiazide diuretics after the new clinical evidence released in December 2002 demonstrating clinical equivalence of thiazides to ACE inhibitors and CCBs. In contrast, prescription of ACE inhibitors declined, accompanied by continuation of a pre-existing increase in the prescription of ARBs, whereas prescription of CCBs remained essentially stable after the new evidence was released. The recorded long- and short-term trends indicate that evidence-based clinical recommendations had an impact on antihypertensive prescribing practices, but the magnitude of impact may be smaller and of more limited duration than desired.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785334     DOI: 10.1161/01.HYP.0000229653.73128.b6

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  27 in total

1.  Difference of antihypertensive prescribing between office- and hospital-based clinics in Taiwan.

Authors:  Wei-Liang Chen; Tung-Wei Kao; Chung-Ching Wang; Yaw-Wen Chang; Li-Wei Wu; Mark L Wahlqvist; Chih-Chieh Chou
Journal:  Int J Clin Pharm       Date:  2012-07-10

2.  Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data.

Authors:  Margrét V Bjarnadóttir; Sana Malik; Eberechukwu Onukwugha; Tanisha Gooden; Catherine Plaisant
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

3.  Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines.

Authors:  Marie Krousel-Wood; Paul Muntner; April Carson; Amanda H Anderson; Erin Delaune; William C Cushman; Jeffrey A Cutler; Linda B Piller; Gary A Goforth; Paul K Whelton
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-16       Impact factor: 3.738

Review 4.  Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.

Authors:  Jeffrey A Cutler; Barry R Davis
Journal:  Circulation       Date:  2008-05-20       Impact factor: 29.690

5.  Imputing observed blood pressure for antihypertensive treatment: impact on population and genetic analyses.

Authors:  Brinda K Rana; Anish Dhamija; Matthew S Panizzon; Kelly M Spoon; Terrie Vasilopoulos; Carol E Franz; Michael D Grant; Kristen C Jacobson; Kathleen Kim; Michael J Lyons; Jeanne M McCaffery; Phyllis K Stein; Hong Xian; Daniel T O'Connor; William S Kremen
Journal:  Am J Hypertens       Date:  2014-02-14       Impact factor: 2.689

6.  National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.

Authors:  Maureen M Okam; Shimon Shaykevich; Benjamin L Ebert; Alan M Zaslavsky; John Z Ayanian
Journal:  Med Care       Date:  2014-07       Impact factor: 2.983

7.  Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort.

Authors:  Emily McDonald; D Michal Freedman; Bruce H Alexander; Michele M Doody; Margaret A Tucker; Martha S Linet; Elizabeth K Cahoon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-08       Impact factor: 4.254

8.  Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies.

Authors:  Huilin Tang; Shuangshuang Fu; Suodi Zhai; Yiqing Song; Jiali Han
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

9.  Screening, treatment, and control of hypertension in US private physician offices, 2003-2004.

Authors:  Jun Ma; Randall S Stafford
Journal:  Hypertension       Date:  2008-03-17       Impact factor: 10.190

10.  Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.

Authors:  Jean-Marie Krzesinski; Eric P Cohen
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.